Atherosclerosis and osteoporosis

Minerva Medica

Volumn 99, Issue 1, 2008, Pages 45-54

  Perez Castrillon J L ^a,b   De Luis, D ^a,b   Duenas Laita, A ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b RD 056/0013 RETICEF ^*

Author keywords

Atherosclerosis; Bone density; Cardiovascular system; Osteoporosis; Risk factors

Indexed keywords

ESTROGEN; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VITAMIN D;

ATHEROSCLEROSIS; BONE DENSITY; BONE REMODELING; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ECONOMIC ASPECT; ENDOTHELIUM; HEREDITY; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; REVIEW;

ATHEROSCLEROSIS; BONE REMODELING; CALCINOSIS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 42049121423     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR. Rates of bone loos is associated with mortality in older women: aprospective study. J Bone Miner Res 2000;15:1974-80.
2. Bauer DC, Palermo L, Black D, Cauley JA. Quantitaive ultrasound and mortality: a prospective study. Osteoporosis Int 2002;13:606-12.
3. Hofbauer LC, Brueck CC, Shanahan CM, Schopper M, Dobnig H. Vascular calcification and osteoporosis, from clinical observation towards molecular understanding. Osteoporosis Int 2007;18:251-9.
4. Bagger YZ, Rasmunssen HB, Alexandersen P, Werge T, Christiansen C, Tankó LB. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporosis Int 2007;18:505-12.
5. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005;352:1685-95.
6. Doherty TM, Fitzpatrick LA, Inoue D, Quiao JH, Fishbein MC, Detrano RC et al. Molecular, endocrine and genetic mechanisms of arterial calcification. Endocr Rev 2004; 25:629-72.
7. Tankó LB, Bagger YZ, Christiansen C. Low BMD in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003;73:15-20.
8. Bagger YZ, Tankó LB, Alexandersen P, Qin G, Christiansen C. Radiographic measure of aortic calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Int Med 2006;259:598-605.
9. Hyder JA, Allison MA, Criqui MH, Wright CM. Association between systemic calcified atherosclerosis and bone density. Calcif Tissue Int 2007;80:301-6.
10. Sinnot B, Syed I, Sevrunkov A, Barengolts E. Coronary calcification and osteoporosis in men and postmenopausal women are independent process associated with aging. Calcif Tissue Int 2006;78:195-202.
11. Shen H, Bielak LF, Streeten EA, Ryan KA, Rumberger JA, Sheedy PF et al. Relationship between vascular calcification and BMD in the Old-order Amish. Calcif Tissue Int 2007;80:244-50.
12. Magnus JH, Broussard DL. Relationship between BMD and myocardial infarction in US adults. Osteoporos Int 2005;16:2053-62.
13. Perez-Castrillon JL, Abad L, Vega G, Sanz-Cantalapiedra A, San Miguel A, Mazón A et al. Bone mineral density, bone remodelling and osteoprotegerin in patients with acute coronary syndrome. Int J Cardiol 2007 [Epub ahead of print]
14. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral BMD in patients with heart failure. Osteoporos Int 2006;17:1420-7.
15. Farhat GN, Newman AB, Sutton-Tyrrell K, Matthews KA, Boudreau R, Schwartz AV et al. The association of BMD measures with incident cardiovascular disease in older adults. Osteoporos Int 2007;18:999-1008.
16. Sennerby U, Farahmand B, Ahlbom A, Ljunghall S, Michaëlsson K. Cardiovascular diseases and future risk of hip fracture in women. Osteoporos Int 2007;18:1355-62.
17. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912-20.
18. Van der Klift M, Pols HA, Hak AE, Witteman JC, Hofman A, De Laet CE. Bone mineral density and the risk of peripheral arterial disease: the Rotterdam Study. Calcif Tissue Intern 2002;70:443-9.
19. Wong SY, Kwok T, Woo J, Lynn H, Griffith JF, Leung J et al. Bone mineral density and the risk of peripheral arterial disease in men and women: results from Mr. and Ms Os, Hong Kong. Osteoporos Int 2005;16:1933-8.
20. Votgt MT, Cauley JA, Kuller LH, Nevitt MC. Bone mineral density and blood flow to the lower extremities: The Study of Osteoporotic Fractures. J Bone Miner Res 1997;12:283-9.
21. Mangiafico RA, Russo E, Riccobene S, Pennisi P, Mangiafico M, D'Amico F et al. Increased prevalence of peripheral arterial disease in osteoporotic postmenopausal women. J Bone Miner Res 2006;24:125-31.
22. Mangiafico RA, Alagona C, Pennisi P, Parisi N, Mangiafico M, Purrello F et al. Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. Osteoporos Int 2008;19:49-56.
23. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PWF. Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif Tissue Int 2001;68:271-6.
24. Samelson EJ, Cupples LA, Broe KE, Hannan MT, O'Donnell CJ, Kiel DP. Vascular calcification in middle age and long-term risk of hip fracture: The Framingham Study. J Bone Miner Res 2007;22:1449-54.
25. Schulz E, Arfai K Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246-53.
26. Jorgensen L, Joakimsen O, Mathiesen EB, Ahmed L, Berntsen GKR, Fonnebo V et al. Carotid plaque echogenicity and risk of nonvertebral fractures in women: a longitudinal population-based study. Calcif Tissue Int 2006;79:207-13.
27. Livshits G. Quantitative genetics of circulating molecules associated with bone metabolism: A review. J Musculoskelet Neuronal Interact 2006;6:47-61.
28. Zaidi M. Skeletal remodelling in health and disease. Nat Med 2007;13:792-801.
29. Mani A, Radhakrishnan J, Wang HE, Mani A, Mani M, Nelson-Williams C et al. LPR6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007;315:1278-82.
30. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25.
31. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the osteoprotegerin gene are assiated with osteoporotic fractures. J Bone Miner Res 2002;17:1744-51.
32. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004;89:3764-8.
33. Lorentzon M, Lorentzon R, Lerner UH, Nordström P. Calcium sensing receptor gene polymorhism, circulating calcium concentrations and BMD in healthy adolescent girls. Eur J Endocrinol 2001;144:257-61.
34. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997;20:303-9.
35. März W, Seelhorst U, Wellnitz B, Tiran B, Obermayer-Pietsch B, Boehm BO et al. Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J Clin Endocrinol Metab 2007;92:2363-9.
36. Cetani F, Pardi E, Borsari S, Vignali E, Dipollina G, Berge V et al. Calcium-sensing receptor gene polymorhism is not associated with BMD in Italian postmenopausal women. Eur J Endocrinol 2003:148:603-7.
37. Perez-Castrillon JL, Sanz A, Silva J, Justo I, Velasco E, Dueñas A. Calcium-sensing receptor gene A986S polymorphism and bone mass in hypertensive women. Arch Med Res 2006;37:607-11.
38. Zarrabeitia MT, Hernandez JL, Valero C, Zarrabeitia AL, Ortiz F, Gonzalez-Macias J et al. Klotho gene polymorphism and male bone mass. Calcif Tissue Int 2007;80:10-4.
39. Imamura A, Okumura K, Ogawa Y, Murakami R, Torigoe M, Numaguchi Y et al. Khloto gene polymorphism may be a genetic risk factor for atherosclerotic coronary artery disease but not for vasospastic angina in Japanese. Clin Chim Acta 2006;371:66-70.
40. Rahman MM, Laher I. Structural and functional alteration of blood vessels caused by cigarette smoking: an overview of molecular mechanisms. Curr Vasc Pharmacol 2007;5:276-92.
41. Fang MA, Frost PG, Iida-Klein A, Hahn TJ. Effects of nicotine on cellular function in UMR 106-01 osteoblast-like cells. Bone 1991;12:283-6.
42. Supervía A, Nogues X, Enjuanes A, Villa J, Mellibovsky L, Serrano S et al. Effect of smoking and smoking cessation on bone mass, bone remodelling, vitamin D, PTH and sex hormones. J Musculoskelet Neuronal Interact 2006;6:234-41.
43. Hollenbach KA Barret-Connor E, Edelstein SL, Holbrook T. Cigarette smoking and BMD in older men and women. Am J Public Health 1993;83:1265-70.
44. Perez-Castrillon JL, Justo I, Sanz-Cantalapiedra A, Pueyo C, Hernandez G, Dueñas A. Effect of the Antihypertensive Treatment on bone Mineral Density and Osteoporotic Fracture. Current Hypert Rev 2005;1:61-6.
45. Perez-Castrillon JL, Justo I, Silva J, Sanz A, Martin-Escudero JC, Igea R et al. Relationship between BMD and angiotensin converting enzyme polymorphism in hypertensive postmenopausal women. Am J Hypertens 2003;16:233-5.
46. Pérez-Castrillón JL, Martín-Escudero JC, Alvarez-Manzanares P, Cortes Sancho R, Iglesias Zamora S, García Alonso M. Hypertension as a risk factor for hip fracture. Am J Hypertens 2005;18:146-7.
47. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition srudy. Arch Intern Med 2005;165:1612-7.
48. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ et al. Study of osteoporotic features research group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001:86:32-8.
49. Cortes-Sancho R, Perez-Castrillón JL, Martin-Escudero JC, Iglesias Zamora S, Alvarez-Manzanares P, Ramos R. Type 2 diabetes mellitus as a risk factor for hip fracture. J Am Geriatr Soc 2004;52:1778-9.
50. Koh JM, Lee YS, Kim KS, Dim DJ, Kim HH, Park JY et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracelular ROS generation. J Bone Miner Res 2006;21:1003-11.
51. Van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, Van der Klift M, De Jonge R, Lindemans J et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
52. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al. Homocysteine as a predictive factor for hip fracturew in older persons. N Engl J Med 2004;350:2033-41.
53. Sawka AM, Ray JG, Yi Q, Josse RG, Lonn E. Randomized clinical trial of homocysteine level-lowering therapy and fractures. Arch Intern Med 2007;167:2136-9.
54. Broulik PD, Kapitola J. Interelations between body weight, cigarette smoking and spine mineral density in osteoporotic Czech women. Endocr Regul 1993;27:57-60.
55. Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sowa H, Chen Q et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J;2002;49:211-7.
56. Cui LH, Shin MH, Chung EK, Lee YH, Kweon SS, Park KS et al. Association between bone mineral densities and serum lipid profiles of pre and post-menopausal rural women in South Korea. Osteoporos Int 2005;16:1975-81.
57. Samelson EJ, Cupples LA, Hannan MT, Wilson PWF, Williams SA, Vaccarino V. Long-term effects of serum cholesterol on BMD in women and men: The Framingham Osteoporosis Study. Bone 2004;34:557-61.
58. Tanko LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women ? Bone 2003;32:8-14.
59. Pérez-Castrillón JL, De Luis D, Martín-Escudero JC, Asensio T, Del Arno R, Izaola I. Non-insulin-dependent diabetes, BMD, and cardiovascular risk factors. J Diabetes Complications 2004;18:317-21.
60. Parhami F, Garfinkel A, Demer LL. Role of lipids in osteoporosis. Arterioscler Thromb Vasc Biol 2000:20:2346-8.
61. Von Muhlen D, Safii S, Jassal SK, Svartberg J, Barret-Connor E. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int 2007;18:1337-44.
62. Gonzalez-Macias J, Olmos Martinez JM. Fisiopatologia de la osteoporosis. Medicine 2006;9:1-7.
63. Ross FP. Interleukin 7 and estrogen-induced bone loss. Trends Endocrinol Metab 2003;14:147-9.
64. Arnal JF, Scarabin PY, Trémollières F, Laurell H, Gourdy P. Estrogens in vascular biology and disease: where do we stand today ? Curr Opin Lipidol 2007;18:554-60.
65. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007:356:2591-602.
66. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
67. Karsenty G. Convergence between bone and energy homeostases: review leptin regulation of bone mass. Cell Matabolism 2006;4:341-8.
68. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006;189:47-60.
69. Schlüter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998;37:34-41.
70. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 2007;292:F1215-F1218.
71. Holick MF. Sunlight and vitamin D for bone health and prevention of autoinmune diseases, cancer and cardiovascular disease. Am J Clin Nutr 2004;80:1678-88.
72. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006;92:39-48.
73. Kato S, Kim MS, Yamakoaka K, Fujiki R. Mechanisms of transcriptional repression by 1,25(OH)2 vitamin D. Curr Opin Nephrol Hypertens 2007;16:297-304.
74. Fahrleitner A, Dobnig H, Obernosterer A, Pilger E, Leb G, Weber K et al. Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J Gen Intern Med 2002;17:633-9.
75. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G et al. The effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease . Am J Cardiol 2007;99:903-5.
76. Zittermann A, Scheleithoff SS, Koerfer R. Vitamin D insufficiency in congestive heart failure: Why and what to do about it ? Heart Fail Rev 2006;11:25-33.
77. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003;88:327-31.
78. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-8.
79. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131-8.
80. Leitinger N. Oxidized phosphlipidis as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 2003;14:421-30.
81. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-90.
82. Kuiper J, Van Puijvelde G, Van Wanrooy E, Van Es T, Habets K, Hauer AD et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr Opin Lipidol 2007;18:521-6.
83. McCormick RK. Osteoporosis: Integrating biomarkers and other diagnostic correlates into the management of bone fragility . Alternative Medicine Review 2007;12:113-45.
84. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005;208:154-68.
85. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
86. Bucay N, Sarosi I Dunstan CR, Morony S, Tarplay J, Caparelli C et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-8.
87. Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O et al. Enhanced T-cell expresión of RANK ligand in acute coronary síndrome. Arterioscler Thromb Vasc Biol 2006;26:857-63.
88. Pennisi P, Signorelli SS, Riccobene S, Celotte G, Di Pino L, La Malfa T et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporosis Int 2004;15:389-95.
89. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
90. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002;106:1192-4.
91. Collin-Osbody P, Rothe L, Anderson F, Nelson M, Maloney W, Osbody P. Receptor activator of NF-⌊B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines and role in human osteoclastogenesis. J Biol Chem 2001;276:20659-72.